-
VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%
•
Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600% by the end of trading yesterday, following the release of positive topline Phase III data for fasedienol, a novel rapid-onset nasal spray treatment for social anxiety disorder (SAD). The PALISADE-2 study demonstrated that fasedienol achieved…
-
Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute
•
A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) is unfolding over alleged conflicts of interest and botched data analysis related to their partnership for the development of rezpegaldesleukin (REZPEG; NKTR-358), a first-in-class regulatory T (Treg) cell stimulator targeting the interleukin-2…
-
BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
•
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its cluster of differentiation-3 (CD3) epidermal growth factor receptor (EGFR)-targeted bispecific antibody (BsAb), BC3448. With this approval, the company will now initiate a Phase I…
-
Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth
•
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the second quarter of 2023, along with recent product highlights and corporate updates. The company reported total product revenues of USD 68.9 million for the quarter, marking a 53% year-on-year (YOY) increase at constant exchange rates.…
-
Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital
•
Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi in a pre-Series B+ financing round, with the investment being solely provided by Cash Capital. Company Background and PipelineFounded in 2018, Gene Cradle has established itself as a leader in the development and manufacturing of…
-
Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a select group of institutional and accredited healthcare specialist investors for a private placement of 138,900,000 ordinary shares, equivalent to 27,780,000 American depositary shares (ADSs), at a purchase price of USD 3.60 per ADS. The agreement…
-
National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services
•
The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient Services for the People,” with the goal of promoting primary healthcare services that equally cover both urban and rural residents. The comprehensive plan consists of 10 key measures: Outpatient Resource Allocation and Specialized Services Enhancing…
-
Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae
•
Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that the US Food and Drug Administration (FDA) has granted approval for Zurzuvae (zuranolone), marking it as the world’s first approved therapy for adults with postpartum depression (PPD). The approval is for Zurzuvae’s use as a…
